Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 11%

Bulls say

Arvinas is a promising biotechnology company, with a pioneering protein degradation platform and a strong pipeline of potential therapies for oncology and neurology indications. The company's partnerships with major pharmaceutical companies, such as Pfizer and Novartis, provide further validation of its approach and potential commercial leverage. With a new CEO in place, focused on building out each area while narrowing the overall portfolio, and a potentially cleaner path to approval for its lead program in PSP, Arvinas has the potential for significant growth and success. Of course, as with any clinical-stage biotechnology company, there are risks involved, including unexpected clinical trial outcomes and competition, but the company's value potential outweighs these risks, making it an attractive investment opportunity.

Bears say

Arvinas is facing tough competition in the market from Biogen's BIIB122 drug, which has so far shown a more promising reduction of LRRK2 protein levels. Despite initial promising biomarker data and a clean safety profile for Arvinas's ARV-102, market credit is unlikely to come until clinical benefit is demonstrated and a successful phase 2b LUMA result is achieved by BIIB.

Arvinas Inc (ARVN) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 9 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.